← ANALYST RATINGS · TIPRANKS
uniQure (QURE): analyst forecast and price target
Analyst consensus
Strong Buy8 Buy2 Hold0 Sell
Ratings of 10 analysts in the last 3 months12-month forecast
Based on 10 price targets given in the last 3 months, the average target is $53.57, the highest $80.00, the lowest $28.00. The average is +146.0% from the last price of $21.78.
Analyst ratings 15
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $21.50 → $21.00−2.3% | Hold | −3.6% | Reiterated | 15.10.26on TipRanks 16:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $21.50 → $21.00−2.3% | Hold | −3.6% | Reiterated | 15.10.26on TipRanks 16:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $21.50 → $21.00−2.3% | Hold | −3.6% | Reiterated | 15.10.26on TipRanks 16:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $22.50 → $22.00−2.2% | Hold | +1.0% | Reiterated | 15.10.26on TipRanks 16:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $21.50 → $21.00−2.3% | Hold | −3.6% | Reiterated | 15.10.26on TipRanks 16:05 | — | |
| Joon Lee★★★★★★★★★★#73 · hits 58% · avg +36.3% | Truist Financial | $27.00 → $48.00+77.8% | Buy | +120.4% | Reiterated | 14.10.26on TipRanks Oct 15 04:35 | −0.4%next day +7.1% | ↗ |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $25.00 → $21.50−14.0% | Hold | −1.3% | Reiterated | 14.10.26on TipRanks 10:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $25.00 → $21.50−14.0% | Hold | −1.3% | Reiterated | 14.10.26on TipRanks 10:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $25.00 → $21.50−14.0% | Hold | −1.3% | Reiterated | 14.10.26on TipRanks 10:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $24.50 → $21.50−12.2% | Hold | −1.3% | Reiterated | 14.10.26on TipRanks 10:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $26.00 → $22.50−13.5% | Hold | +3.3% | Reiterated | 14.10.26on TipRanks 10:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $24.50 → $21.50−12.2% | Hold | −1.3% | Reiterated | 14.10.26on TipRanks 10:05 | — | |
| Eliana Merle★★★★★★★★★★#4163 · hits 45% · avg +3.0% | Barclays | $60.00 → $28.00−53.3% | Hold | +28.6% | Downgrade | 05.10.26on TipRanks 07:40 | −3.5%next day +0.6% · 5 days −4.6% | ↗ |
| Luca Issi★★★★★★★★★★#11187 · hits 39% · avg −2.1% | RBC Capital | $65.00 → $48.00−26.2% | Buy | +120.4% | Assigned | 02.10.26on TipRanks Sep 29 15:06 | −37.1%next day −1.2% · 5 days −7.9% | ↗ |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $40.00 → $25.00−37.5% | Hold | +14.8% | Reiterated | 30.09.26on TipRanks 11:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $39.00 → $25.00−35.9% | Hold | +14.8% | Reiterated | 30.09.26on TipRanks 11:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $40.00 → $25.00−37.5% | Hold | +14.8% | Reiterated | 30.09.26on TipRanks 11:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $39.00 → $24.50−37.2% | Hold | +12.5% | Reiterated | 30.09.26on TipRanks 11:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $41.00 → $26.00−36.6% | Hold | +19.4% | Reiterated | 30.09.26on TipRanks 11:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $39.00 → $24.50−37.2% | Hold | +12.5% | Reiterated | 30.09.26on TipRanks 11:05 | — | |
| Eliana Merle★★★★★★★★★★#4163 · hits 45% · avg +3.0% | Barclays | $60.00 | Buy | +175.5% | Reiterated | 30.09.26on TipRanks 05:25 | −1.2%next day −3.4% · 5 days −6.1% | ↗ |
| Salveen Richter★★★★★★★★★★#967 · hits 51% · avg +12.5% | Goldman Sachs | $46.00 → $31.00−32.6% | Hold | +42.3% | Assigned | 30.09.26on TipRanks Sep 29 21:05 | −1.2%next day −3.4% · 5 days −6.1% | ↗ |
| Patrick Trucchio★★★★★★★★★★#79 · hits 58% · avg +37.9% | H.C. Wainwright | $80.00 | Buy | +267.3% | Reiterated | 30.09.26on TipRanks Sep 29 12:45 | −37.1%next day −1.2% · 5 days −7.9% | ↗ |
| Yanan Zhu★★★★★★★★★★#1136 · hits 36% · avg +15.3% | Wells Fargo | $75.00 | Buy | +244.4% | Reiterated | 29.09.26on TipRanks 15:20 | −37.1%next day −1.2% · 5 days −7.9% | ↗ |
| Lachlan Hanbury Brown★★★★★★★★★★#11394 · hits 35% · avg −5.4% | William Blair | — | Buy | — | Reiterated | 29.09.26on TipRanks 11:55 | −37.1%next day −1.2% · 5 days −7.9% | ↗ |
| Paul Matteis★★★★★★★★★★#473 · hits 53% · avg +17.6% | Stifel Nicolaus | — | Buy | — | Reiterated | 29.09.26on TipRanks 08:12 | −37.1%next day −1.2% · 5 days −7.9% | ↗ |
| Joseph Thome★★★★★★★★★★#320 · hits 57% · avg +24.8% | TD Cowen | — | Buy | — | Reiterated | 02.09.26on TipRanks Sep 3 10:25 | −3.8%next day −4.0% · 5 days −2.8% | ↗ |
| Rudy Li★★★★★★★★★★#235 · hits 63% · avg +76.1% | Wolfe Research | $65.00 | Buy | +198.4% | Upgrade | 29.07.26on TipRanks 18:17 | +3.6%next day +2.7% · 5 days +3.9% | ↗ |
| Joseph Schwartz★★★★★★★★★★#135 · hits 54% · avg +31.9% | Leerink Partners | $36.00 → $70.00+94.4% | Buy | +221.4% | Reiterated | 17.06.26on TipRanks Jun 18 07:31 | +79.7%next day −4.9% · 5 days +2.6% | ↗ |
| Kristen Kluska★★★★★★★★★★#457 · hits 48% · avg +23.3% | Cantor Fitzgerald | — | Buy | — | Upgrade | 17.06.26on TipRanks 11:50 | +79.7%next day −4.9% · 5 days +2.6% | ↗ |
| Daniil Gataulin★★★★★★★★★★#2392 · hits 39% · avg +14.9% | Chardan Capital | $37.00 | Buy | +69.9% | Reiterated | 05.05.26on TipRanks May 6 00:11 | +1.5%next day +6.5% · 5 days +35.5% | ↗ |
| Unknown Analyst | Guggenheim | $95.00 | Buy | +336.2% | Reiterated | 05.05.26on TipRanks 11:45 | +1.5%next day +6.5% · 5 days +35.5% | ↗ |
| No ratings for this filter. | ||||||||
Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst
Best analysts covering uniQure
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 02.10.26: target $59.83 at a price of $23.37 (+156.0%); now: $53.57 at $21.78 (+146.0%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 15 | 10 | 11 | 7 | 10 | 8 |
| Buy | 4 | 10 | 12 | 10 | 5 | 3 |
| Hold | 10 | 4 | 5 | 3 | 4 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 10.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.92 (from $-1.22 to $-0.74). Last quarter: $-1.22.
Sales
Next quarter’s sales estimate — $6M (from $2M to $10M). Last quarter: $6M.
Best top-analyst consensus in the sector · Healthcare
About uniQure
- CEO: Matthew C. Kapusta
- Employees: 221
- Paasheuvelweg 25, Amsterdam, NH, 1105 BP, NL
- www.uniqure.com
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in phase I/II clinical study for the treatment of Huntington’s disease. The company also develops AMT-260, which is in phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Data from the stock’s TipRanks forecast page, read 58 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗